Table 1. 2019 update on drug development.

Trials	156
Agents tested	132
Main primary mechanisms of action and objectives of trials
Cognitive enhancement	19 (14)
Treatment of NPS and BPSD	14 (11)
Disease modification	96 (73)
Main primary targets
Amyloid	38 (40)
Tau	17 (18)
Types of agents
Disease-modifying biologics
Disease-modifying small molecules
Symptomatic (system-reducing small molecules)

Data presented as n or n (%).

BPSD = behavioral and psychological symptoms of dementia; NPS = neuropsychiatric symptoms.